SCHEMBL2451471

SCHEMBL2451471

Cc1nccn1-c1ccc(Nc2nc3c(c(N4c5ccccc5CC4CO)n2)CN(C(=O)O)CC3)cc1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.34
CYP2D6 P10635 2/20 0.34
PORCN Q9H237 1/20 0.34
ROCK2 O75116 1/20 0.34
PDGFRB P09619 3/20 0.34
SYK P43405 1/20 0.33
CYP2C9 P11712 1/20 0.32
CYP2C19 P33261 1/20 0.32
KCNH2 Q12809 1/20 0.32
ENPP2 Q13822 2/20 0.32
PDE10A Q9Y233 4/20 0.32
KDR P35968 1/20 0.32
TRPV1 Q8NER1 1/20 0.32
RIPK1 Q13546 1/20 0.32
MAPT P10636 1/20 0.31
EGFR P00533 2/20 0.31
CSF1R P07333 1/20 0.31
GPBAR1 Q8TDU6 1/20 0.31
JAK2 O60674 1/20 0.31
JAK3 P52333 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2848559 0.91 MAPT (0.43) PDE10ATRPV1MAPTJAK2JAK3
SCHEMBL2848556 0.91 MAPT (0.43) PDE10ATRPV1MAPTJAK2JAK3
SCHEMBL2446909 0.91 ROCK2 (0.39) CYP3A4CYP2D6PORCNROCK2SYK
SCHEMBL2477814 0.91 ROCK2 (0.39) CYP3A4CYP2D6PORCNROCK2SYK
SCHEMBL2477810 0.91 ROCK2 (0.39) CYP3A4CYP2D6PORCNROCK2SYK
SCHEMBL2483931 0.84 SYK (0.32) CYP3A4CYP2D6PORCNROCK2SYK
SCHEMBL2483928 0.84 SYK (0.32) CYP3A4CYP2D6PORCNROCK2SYK
SCHEMBL2445594 0.78 SYK (0.39) CYP3A4CYP2D6PORCNROCK2PDGFRB
SCHEMBL2483361 0.78 ROCK2 (0.40) CYP3A4CYP2D6PORCNROCK2PDGFRB
SCHEMBL2476632 0.76 CYP3A4 (0.37) CYP3A4CYP2D6PORCNROCK2PDGFRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8188101-B2 Dihydropyridopyrimidines for the treatment of AB-related pathologies ASTRAZENECA AB (SE) 2012-05-29 US disclosed
EP-2367826-A1 MODULATORS OF AMYLOID BETA. AstraZeneca AB (SE) 2011-09-28 EP disclosed
US-20100130495-A1 COMPOUNDS 563 ASTRAZENECA AB (SE) 2010-05-27 US disclosed
WO-2010053438-A1 MODULATORS OF AMYLOID BETA. ASTRAZENECA AB (SE) 2010-05-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130495-A1 COMPOUNDS 563 BACE1, PSEN1, PSEN2 CYP3A4 4727/4885CYP2D6 4725/4885PORCN 4595/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.